4th Laupheim Biotech Days
Themes
In this conference with the title "Fusion Proteins - delivering novel therapeutic options" we are examining the state of the art in developing fusion proteins as biopharmaceuticals, shedding light on the immense potential of design and functionality.
Date
June 13 to 14, 2016
Venue
Schloss Großlaupheim, 88471 Laupheim, Germany
Program
| 14:00 | Tour of Rentschler’s facility Rentschler Biotechnologie GmbH Laupheim, Germany |
|---|---|
| 17:00 | Reception & exhibition Kulturhaus Schloss Großlaupheim Laupheim, Germany |
| 18:00 | Welcome Rentschler Biotechnologie GmbH Laupheim, Germany Genetic Engineering in Cell Culture Engineering: A forward-looking review Hansjörg Hauser |
| 19:30 | Dinner at the historical castle Kulturhaus Schloss Großlaupheim Laupheim, Germany |
| 09:00 | Welcome Stefan Schmidt |
|---|---|
| 09:10 | Therapeutic fusion proteins: Current trends and challenges Stefan Schmidt |
| 09:30 | PASylation: design of biologics with extended plasma half-life by genetic fusion with structurally disordered Pro/Ala-rich sequences as an alternative to chemical PEGylation Arne Skerra |
|---|---|
| 10:00 | Recombinant albumin fusion proteins and half-life extension Hubert Metzner |
| 10:30 | Coffee break |
| 11:00 | Hexavalent fusion proteins for cancer treatment and immune modulation: TRAIL, CD40L and beyond Oliver Hill |
|---|---|
| 11:30 | TNF superfamily (TNFSF) ligand fusion proteins with enhanced receptor stimulatory activity Harald Wajant |
| 12:00 | Antibody-ribonuclease fusion proteins (ImmunoRNases) for cancer therapy Michaela Arndt |
| 12:30 | Lunch break and exhibition |
| 13:30 | Armed antibodies (from the bench to the clinic), with a special focus on antibody-cytokine fusion proteins Dario Neri |
|---|---|
| 14:00 | Fynomabs Wibke Lembke |
| 14:30 | Boosting natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies and bispecific immunoligands Matthias Peipp |
| 15:00 | Coffee break |
| 15:30 | Development of TandAbs for hematological and solid Tumors Erich Rajkovic |
|---|---|
| 16:00 | Nonclinical assessment of bispecific T-cell engaging antibody constructs (BiTE ®) and their transition into the clinic Benno Rattel |
| 16:30 | Old target - new mode of action: how to create truly potent anti-ErbB2 agents Martin Schwill |
| 17:00 | Final remarks and farewell “Get-Together” |
Beverage Sponsor
Gold Sponsors
Silver Sponsors
Exhibitors
